132 related articles for article (PubMed ID: 23035026)
1. A survey of quality attributes of virus spike preparations used in clearance studies.
Miesegaes G; Lute S; Dement-Brown J; Kaushal S; Strauss D; Chen D; Brorson K
PDA J Pharm Sci Technol; 2012; 66(5):420-33. PubMed ID: 23035026
[TBL] [Abstract][Full Text] [Related]
2. Limits in virus filtration capability? Impact of virus quality and spike level on virus removal with xenotropic murine leukemia virus.
Roush DJ; Myrold A; Burnham MS; And JV; Hughes JV
Biotechnol Prog; 2015; 31(1):135-44. PubMed ID: 25395156
[TBL] [Abstract][Full Text] [Related]
3. The Use of Bayesian Hierarchical Logistic Regression in the Development of a Modular Viral Inactivation Claim.
Banton D; Vacante D; Bulthuis B; Goldstein J; Wineburg M; Schreffler J
PDA J Pharm Sci Technol; 2019; 73(6):552-561. PubMed ID: 31101710
[TBL] [Abstract][Full Text] [Related]
4. Achieving a Successful Scale-Down Model and Optimized Economics through Parvovirus Filter Validation using Purified TrueSpikeTM Viruses.
De Vilmorin P; Slocum A; Jaber T; Schaefer O; Ruppach H; Genest P
PDA J Pharm Sci Technol; 2015; 69(3):440-9. PubMed ID: 26048749
[TBL] [Abstract][Full Text] [Related]
5. Meeting report--workshop on virus removal by filtration: trends and new developments.
Willkommen H; Blümel J; Brorson K; Chen D; Chen Q; Gröner A; Kreil TR; Robertson JS; Ruffing M; Ruiz S
PDA J Pharm Sci Technol; 2013; 67(2):98-104. PubMed ID: 23569071
[TBL] [Abstract][Full Text] [Related]
6. Use of MMV as a Single Worst-Case Model Virus in Viral Filter Validation Studies.
Gefroh E; Dehghani H; McClure M; Connell-Crowley L; Vedantham G
PDA J Pharm Sci Technol; 2014; 68(3):297-311. PubMed ID: 25188350
[TBL] [Abstract][Full Text] [Related]
7. Proceedings of the 2017 Viral Clearance Symposium, Session 2.1: DSP Unit Operations-Virus Filtration/Inactivation.
Kreil TR; Roush D
PDA J Pharm Sci Technol; 2018; 72(5):470-478. PubMed ID: 30030356
[TBL] [Abstract][Full Text] [Related]
8. Proceedings of the 2019 Viral Clearance Symposium, Session 6: Virus-Retentive Filtration.
O'Donnell S; Bolton G
PDA J Pharm Sci Technol; 2022; 76(4):349-357. PubMed ID: 34911825
[TBL] [Abstract][Full Text] [Related]
9. Analysis of viral clearance unit operations for monoclonal antibodies.
Miesegaes G; Lute S; Brorson K
Biotechnol Bioeng; 2010 Jun; 106(2):238-46. PubMed ID: 20073086
[TBL] [Abstract][Full Text] [Related]
10. Proceedings of the 2017 Viral Clearance Symposium, Session 6: Ensuring Viral Safety in Continuous Processing.
Johnson SA; Roush D
PDA J Pharm Sci Technol; 2018; 72(5):516-524. PubMed ID: 30030352
[TBL] [Abstract][Full Text] [Related]
11. Characterization of ionic strength for X-MuLV inactivation by low pH treatment for monoclonal antibody purification.
Daya J; Cusick V; Mattila J
Biotechnol Bioeng; 2023 Jun; 120(6):1605-1613. PubMed ID: 36924035
[TBL] [Abstract][Full Text] [Related]
12. RUNspike, a complementary virus filter spiking method: a solution to the problem of reduced throughput due to the addition of the virus spike.
Parrella J; Wu Y; Kahn DW; Genest P
PDA J Pharm Sci Technol; 2009; 63(6):547-58. PubMed ID: 20169861
[TBL] [Abstract][Full Text] [Related]
13. Development of a transient inline spiking system for evaluating virus clearance in continuous bioprocessing-Proof of concept for virus filtration.
Malakian A; Jung SY; Afzal MA; Carbrello C; Giglia S; Johnson M; Miller C; Rayfield W; Boenitz D; Cetlin D; Zydney AL
Biotechnol Bioeng; 2022 Aug; 119(8):2134-2141. PubMed ID: 35470427
[TBL] [Abstract][Full Text] [Related]
14. Multiplex RT Q-PCR assay for simultaneous quantification of three viruses used for validation of virus clearance by biopharmaceutical production.
Lute S; Wang H; Sanchez D; Barletta J; Chen Q; Brorson K
Biologicals; 2009 Oct; 37(5):331-7. PubMed ID: 19683941
[TBL] [Abstract][Full Text] [Related]
15. Use of a noninfectious surrogate to predict minute virus of mice removal during nanofiltration.
Cetlin D; Pallansch M; Fulton C; Vyas E; Shah A; Sohka T; Dhar A; Pallansch L; Strauss D
Biotechnol Prog; 2018 Sep; 34(5):1213-1220. PubMed ID: 30194917
[TBL] [Abstract][Full Text] [Related]
16. Proceedings of the 2017 Viral Clearance Symposium, Session 2.2: DSP Unit Operations-Purification Unit Operations.
Roush D; Kreil TR
PDA J Pharm Sci Technol; 2018; 72(5):479-487. PubMed ID: 30030354
[TBL] [Abstract][Full Text] [Related]
17. Proceedings of the 2017 Viral Clearance Symposium Session 5: Facility Risk Mitigation.
Ma J; Kreil TR
PDA J Pharm Sci Technol; 2018; 72(5):511-515. PubMed ID: 30030359
[TBL] [Abstract][Full Text] [Related]
18. Proceedings of the 2019 Viral Clearance Symposium, Session 5: Viral Inactivation.
Ma J
PDA J Pharm Sci Technol; 2022; 76(4):339-348. PubMed ID: 34911831
[TBL] [Abstract][Full Text] [Related]
19. Impact of virus preparation quality on parvovirus filter performance.
Slocum A; Burnham M; Genest P; Venkiteshwaran A; Chen D; Hughes J
Biotechnol Bioeng; 2013 Jan; 110(1):229-39. PubMed ID: 22766979
[TBL] [Abstract][Full Text] [Related]
20. Proceedings of the 2019 Viral Clearance Symposium, Session 8. Conference Summary: Key Discussion and Outcomes, Pending Questions, and Proposed Experiments and Actions.
Bolton G
PDA J Pharm Sci Technol; 2022; 76(4):362-367. PubMed ID: 34911826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
